nicotinamide adenine dinucleotide

nicotinamide adenine dinucleotide
Name	Nicotinamide adenine dinucleotide
Formula	C21H27N7O14P2 (approx.)
Molar mass	~663.4 g·mol−1 (NAD+)
Other names	NAD, NAD+

nicotinamide adenine dinucleotide

Nicotinamide adenine dinucleotide is a ubiquitous coenzyme involved in cellular redox chemistry, energy metabolism, and signaling. Discovered through early biochemical studies tied to Nobel Prize work, it participates in pathways central to mitochondrial function, glycolysis, and aging research. Its role intersects with pharmacology, clinical diagnostics, and biotechnology in contexts ranging from metabolic disorders to neurodegeneration.

Structure and chemical properties

NAD+ is composed of two nucleotides joined through their phosphate groups, one containing an adenine moiety and the other a nicotinamide moiety; the dinucleotide architecture was elucidated in studies related to Nobel Prize investigations into enzyme catalysis and metabolic regulation. The oxidized form, NAD+, and the reduced form, NADH, differ by a hydride ion on the nicotinamide ring; chemical behavior such as redox potential and pKa values are important for enzymology in systems studied by laboratories affiliated with institutions like Max Planck Society, Massachusetts Institute of Technology, and Rockefeller University. Crystallographic characterization in complexes with dehydrogenases has employed techniques refined at facilities such as European Molecular Biology Laboratory, Brookhaven National Laboratory, and Lawrence Berkeley National Laboratory.

Biological roles and metabolism

NAD+ functions as an essential electron carrier in central metabolic pathways including glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation, processes investigated by researchers at Harvard University, University of Cambridge, and Stanford University. It serves as a substrate for NAD+-consuming enzymes such as sirtuins and poly(ADP-ribose) polymerases, linking it to chromatin regulation and DNA repair studies pursued at University of California, San Francisco, Columbia University, and Johns Hopkins University. NAD+ levels influence signaling pathways implicated in lifespan and age-related disease models used in labs associated with National Institutes of Health, Salk Institute, and Cold Spring Harbor Laboratory.

Redox reactions and enzymatic functions

In redox reactions NAD+ accepts a hydride to form NADH, enabling dehydrogenases such as lactate dehydrogenase, alcohol dehydrogenase, and malate dehydrogenase to catalyze substrate interconversions characterized in enzymology texts and by groups at University of Oxford, University of Chicago, and Yale University. NADPH, the phosphorylated form produced by the pentose phosphate pathway and isocitrate dehydrogenase, provides reducing power for biosynthetic enzymes and antioxidant defense, topics studied in contexts like research programs at Imperial College London, University of Toronto, and ETH Zurich. NAD+-dependent enzymes include sirtuins (linked to research at Buck Institute for Research on Aging), PARPs (investigated in cancer biology at MD Anderson Cancer Center), and ADP-ribosyltransferases (examined at Karolinska Institutet).

Biosynthesis and salvage pathways

De novo NAD+ biosynthesis originates from tryptophan in pathways characterized in biochemical work connected to University of Göttingen, University of Pennsylvania, and Nagoya University, while salvage pathways recycle nicotinamide and nicotinic acid via enzymes such as nicotinamide phosphoribosyltransferase (NAMPT), whose regulation has been explored at National Cancer Institute, Université Paris Cité, and University of Tokyo. Precursor supplementation strategies using nicotinamide riboside and nicotinamide mononucleotide have been developed and trialed by groups at Ecole Polytechnique Fédérale de Lausanne, University of Washington, and biotech firms collaborating with Wellcome Trust-funded consortia. Genetic defects in enzymes of NAD+ metabolism have been mapped in studies involving clinical centers such as Mayo Clinic and Great Ormond Street Hospital.

Clinical significance and biomedical applications

Altered NAD+ metabolism is implicated in metabolic diseases, neurodegenerative disorders, and cancer, with translational research programs at institutions including Mount Sinai Hospital, Cleveland Clinic, and Karolinska University Hospital. NAD+ precursors are under investigation in clinical trials overseen by organizations like Food and Drug Administration-regulated programs and funded studies from European Commission initiatives; applications include attempts to modulate mitochondrial dysfunction in models studied at Dana-Farber Cancer Institute and Paul Ehrlich Institute. Diagnostics measuring redox state and NAD+/NADH ratios inform therapeutic strategies in intensive care settings at centers such as Toronto General Hospital and Guy's and St Thomas' NHS Foundation Trust.

Analytical methods and measurement

Quantification of NAD+ and NADH employs spectrophotometry, high-performance liquid chromatography, and mass spectrometry platforms developed and standardized in core facilities at National Institute of Standards and Technology, EMBL-EBI, and Thermo Fisher Scientific collaborations. Isotopic tracer studies using labeled precursors are conducted in metabolic flux experiments at laboratories affiliated with Lawrence Livermore National Laboratory, Max Delbrück Center for Molecular Medicine, and Vanderbilt University Medical Center. Imaging techniques to assess NADH autofluorescence in tissues have been applied in research at Karolinska Institutet, University College London, and University of Melbourne.

Category:Nucleotides